Award to help fund preclinical studies of EVŌQ Bio's novel inhalation therapeutic for treatment of pulmonary bacterial infections of patients with cystic fibrosis.
SALT LAKE CITY, May 18, 2022 /PRNewswire-PRWeb/ -- EVŌQ Bio, an early-stage pharmaceutical company developing novel therapeutics against bacterial and fungal pathogens, today announced that it will receive US$378,500 to support the preclinical testing of its lead asset for the treatment of multi-drug resistant pulmonary bacterial infections in patients diagnosed with cystic fibrosis.
"Multi-drug resistant bacterial infections continue to have significant, deleterious impact on cystic fibrosis patients", said David Nilson, Vice President of EVŌQ Bio. "Our novel therapeutic has the potential to be a first-line, stand-alone treatment against pseudomonas and burkholderia infections. The Cystic Fibrosis Foundation's generous support and guidance is allowing us to move our technology forward in a way we believe will have significant impact to the cystic fibrosis community, as well as for those suffering from various forms of pulmonary bacterial infections."
EVŌQ Bio's poly-therapeutic platform leverages nano-technology in the development of antimicrobial applications ranging from pharmaceutical development to fungal/bacterial/biofilm inhibition in implanted/inserted medical devices. Our lead asset targets bacterial infections in the lungs, and its novel mechanism of action disrupts bacterial metabolic activity.
An earlier award from the Cystic Fibrosis Foundation in 2019 allowed us to confirm in vitro efficacy against nine bacteria (64 isolates) that include pseudomonas, staphylococcus, burkholderia and other gram-negative pathogens, while exhibiting no drug resistance. This award will fund dose range finding studies.
Media Contact
Zach Jacob, EVŌQ Nano, 1 8017559628, [email protected]
SOURCE EVŌQ Nano
Share this article